Type 2 diabetes is a complex and progressive disease that has reached epidemic proportions worldwide ([@B1]). In the U.S., diabetes is the third cause of death for women and the fourth for men ([@B2]). Tight glycemic control, to maintain a hemoglobin A~1c~ (HbA~1c~) concentration of \<7%, is recommended for all nonpregnant adults with diabetes to minimize the risk of long-term microvascular (retinopathy, nephropathy, neuropathy) complications ([@B3],[@B4]). The HbA~1c~ goal is currently achieved in ∼50% of patients with type 2 diabetes, at least in selected populations ([@B3]).

Although traditionally used as a final treatment option, insulin has been recently recommended by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) as a third-line treatment after diet, exercise, and metformin fail to reach or maintain an HbA~1c~ of \<7% ([@B5]). According to the National Health Interview Survey, 28% of patients with type 2 diabetes are using insulin, alone (16%) or combined with oral antidiabetic drugs (12%) ([@B6]). The choice of an initial insulin regimen for people with type 2 diabetes, in whom oral drugs have failed, may be a difficult one because hypoglycemia and the fear of developing hypoglycemia remain substantial barriers to the initiation and optimal use of insulin ([@B7]).

Insulin analogs are modified human insulins developed to address the limitations of human insulin preparations to replicate the pattern of basal and postprandial endogenous secretion of insulin ([@B8]). Conversion of the insulin market to analogs, estimated to be 40% 45% in 2005, is projected to reach saturation within 2010 ([@B9]). Systematic reviews of insulin analogs have been published previously ([@B10]--[@B13]). Compared with human insulins, rapid, biphasic (premixed), and basal (long-acting) insulin analogs offer some benefit in better glycemic control and reduced hypoglycemia ([@B10],[@B12],[@B13]). However, we did not identify any reviews that evaluated the proportion of patients with type 2 diabetes achieving the HbA~1c~ target \<7% with insulin analogs. In this article, we performed a meta-analysis of the randomized controlled trials (RCTs) that compared the effect of different insulin regimens based on insulin analogs.

RESEARCH DESIGN AND METHODS {#s5}
===========================

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist for reporting systematic reviews and meta-analyses ([@B14]).

Data sources {#s6}
------------

We searched MEDLINE (1966 to January 2010), EMBASE (1980 to January 2010), the Cochrane Central Register of Controlled Trials, and CINAHL from inception to January 2010. The main search concepts were type 2 diabetes, hemoglobin A~1c~, long-acting insulin analogs, short-acting insulin analogs, biphasic insulin analogs, glargine, detemir, neutral protamine lispro, lispro, aspart, glulisine, randomized controlled trials, and clinical trials. We also reviewed reference lists of included articles, the US Food and Drug Administration and European Medicines Agency Web sites for the insulin analogs, as well as Web sites of public registries of clinical trials (ClinicalTrials.gov and ClinicalStudyResults.org).

Study selection {#s7}
---------------

We included RCTs if *1*) patients aged \>18 years with a diagnosis of type 2 diabetes, as defined by criteria current at the time of the trial ([@B15]) were included; *2*) different insulin regimens (basal, biphasic, prandial or basal-bolus) using insulin analogs were evaluated; and *3*) the proportion of diabetic patients reaching the HbA~1c~ goal of ≤7% was reported. We included crossover trials with at least 12 weeks of follow-up before and after the crossover phase. The search had no language restriction; however, we excluded reviews, editorials, comments, letters, and abstracts. Trials were rejected if the intervention time was \<3 months, the number of patients in any arm was \<30 patients, or comparisons were between insulin analogs and conventional insulins within the same or different regimens.

Quality assessment {#s8}
------------------

Two investigators (D.G. and K.E.) identified relevant publications and abstracted the data, and any disagreements were resolved by consensus. Methodologic quality was scored using criteria set out by Jadad et al. ([@B16]). This 5-point quality scale includes points for randomization (described as randomized, 1 point; table of random numbers or computer-generated randomization, additional 1 point), double-blind (described as double-blind, 1 point; use of masking such as identical placebo, additional 1 point), and follow-up (the numbers and reasons for withdrawal in each group are stated; 1 point) in the report of an RCT. We gave an additional point if the analysis was by intention-to-treat. We considered scores of ≤2 as low quality and a score of ≥3 as high quality because none of the studies were double-blinded, due to the visibly different properties of the comparators.

Insulin regimens {#s9}
----------------

We compared four insulin regimens: the biphasic regimen consisted of the biphasic (premixed) insulin analogs lispro 25/75, lispro 50/50, aspart 30/70, aspart 50/50, and aspart 70/30, with the numbers denoting the percentage of the rapid-acting/the long-acting component;the basal regimen consisted of basal insulin analogs comprising the long-acting insulins glargine, detemir, and lispro/neutral protamine lispro;the prandial regimen consisted of prandial insulin analogs, comprising short-acting insulins lispro, aspart, and glulisine; andthe basal-bolus regimen consisted of any combination of prandial and basal insulin analogs.No studies comparing basal or prandial with basal-bolus regimens met the inclusion criteria.

Data synthesis and analysis {#s10}
---------------------------

The proportion of patients with HbA~1c~ \<7% at the end of treatment was the primary outcome. Secondary outcomes were hypoglycemic events and weight gain. Statistically, binomial proportion lacks consensus over the calculation of the confidence intervals. We transformed the proportions into a quantity suitable for the usual fixed and random-effects summaries (the Freeman-Tukey variant of the arc sine square root transformed proportion) ([@B17]). The pooled proportion is calculated as a back-transformation of the weighted mean of the transformed proportions, using inverse arc sine variance weights for the fixed-effects model and DerSimonian-Laird weights ([@B18]) for the random-effects model.

Denominators used for calculating the response rate on each treatment group were those reported within original studies as eligible patients coming from randomization. The association between exposure (treatments) and outcome (proportions of patients with HbA~1c~ \<7%) was measured by the odds ratio (OR). When the OR and 95% CIs were available, we transformed them into logOR and calculated the corresponding variance and standard error using the formula proposed by Greenland ([@B19]). When the OR was not directly available from the article, we calculated it from tabular data and used the Woolf formula to evaluate the standard error of the logOR ([@B20]). If tabular data were not given and only response rate was available, the number of responses was calculated by multiplying the response rate by the number of randomized/eligible patients. Pooled OR with 95% CI was estimated, pooling the study-specific estimates by random-effects models fitted using SAS (PROC MIXED) software (SAS Institute) with maximum likelihood estimate. These models provided estimates adjusted for the heterogeneity between studies and the correlation within studies given by the randomized studies with more than two groups. That is a conservative approach because it raises the variability caused by the correlation within study, providing, as a result, wider and more reliable CIs.

Heterogeneity of the effect across studies was assessed by *Q*^2^ statistics, which is distributed as χ^2^ statistics. A value of *P* \< 0.10 was used to indicate lack of homogeneity among effects. *I*^2^ statistics were provided to quantify the percentage of total variation across studies that was attributable to heterogeneity rather than to chance ([@B21]). A value \>50% represented substantial variability. The method of Macaskill et al. ([@B22]) was used for assessing publication bias. It consists of a funnel-plot regression of log(RR) or log(OR) on the sample size, weighted by the inverse of the pooled variance.

For hypoglycemic events and weight gain, we recorded the mean difference between groups, along with its measure of dispersion. If no measure of dispersion was reported for the between-group difference, we conservatively estimated it by the worst ratio between mean and standard deviation among the available studies. If a trial reported the number of episodes in each group or reported an event rate in a form other than episodes per patient per 30 days, we converted this information into episodes per patients per 30 days.

RESULTS {#s11}
=======

We identified 2,650 citations, of which we reviewed 126; of these, 16 ([@B23]--[@B38]) performed comparisons between different insulin regimens and were included in the meta-analysis ([Supplementary Fig. 1](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-1710/-/DC1)). Most trials were multinational and sponsored by industry. All studies were RCTs ([Table 1](#T1){ref-type="table"}): among these, 13 were parallel group and 3 ([@B23],[@B24],[@B27]) were crossover. All studies were of open-label design. Trial duration was 3 to 36 months. The trials enrolled a total of 7,759 patients (range, 60--2,091). Patients were a mean age of 58.2 years, with slight prevalence of male sex (55.6%). The study population had a median HbA~1c~ level of 8.6% (interquartile range 8.4--9.1%).

###### 

Characteristics of the randomized controlled trials included in the meta-analysis

  Trials (first author, year)   *N*    Mo     Insulin regimen   Design analog (shot/day)      Age(years)   Male (%)   OHAs          \< /≤ 7%   Naïve   Start HbA~1c~   Titration   Statistics   Quality score   Insulin dose (units/kg)
  ----------------------------- ------ ------ ----------------- ----------------------------- ------------ ---------- ------------- ---------- ------- --------------- ----------- ------------ --------------- -------------------------
  Malone, 2004 ([@B23])         105    4      Biphasic          CO Lispro25 (×2)              55.3         62.3                                        8.7%                                                     0.62
                                              Basal             Glargine                      55.3         62.3       Met           ≤          Yes     8.7%            No          No ITT       3               0.57
  Malone, 2005 ([@B24])         97     4      Biphasic          CO Lispro25 (×2)              59.3         42                                          8.5%                                                     0.42
                                              Basal             Glargine                      59.3         42         Met           ≤          No      8.5%            No          ITT          2               0.28
  Raskin, 2005 ([@B25])         233    6      Biphasic          P Aspart30 (×2)               52.6         53                                          9.7%                                                     0.82
                                              Basal             Glargine                      52.3         57         Met + Pio     \<         Yes     9.8%            Yes         ITT          2               0.55
  Kann, 2006 ([@B26])           255    6      Biphasic          P Aspart30 (×2)               61.5         53.9                                        9.2%                                                     0.39
                                              Basal             Glargine                      61           48.8       Glimepiride   \<         Mix     8.9%            No          ITT          2               0.39
  Jacober, 2006 ([@B27])        60     4      Biphasic          CO Lispro50 (×2) + Lispro25   54.9         56.7                                        9.2%                                                     0.35
                                              Basal             Glargine                      54.9         56.7       Met/Su/Tzd    ≤          Yes     9.2%            No          No ITT       2               0.28
  Kazda, 2006 ([@B28])          107    6      Biphasic          P Lispro50 (×3)               59.4         54                                          8.1%                                                     0.59
                                              Basal             Glargine                      59.4         54         No            \<         Yes     8.1%            No          ITT          2               0.43
  Kazda, 2006 ([@B28])          106    6      Biphasic          P Lispro50 (×3)               59.4         54                                          8.1%                                                     0.59
                                              Prandial          Lispro (×3)                   59.4         54         No            \<         Yes     8.2%            No          ITT          2               0.50
  Kazda, 2006 ([@B28])          105    6      Prandial          P Lispro (×3)                 59.4         54                                          8.2%                                                     0.50
                                              Basal             Glargine                      59.4         54         No            \<         Yes     8.1%            No          ITT          2               0.43
  Holman, 2007 ([@B29])         469    12     Biphasic          P Aspart30 (×2)               61.7         64.1                                        8.6%                                                     0.53
                                              Basal             Detemir                       61.7         64.1       Met + Su      ≤          Yes     8.4%            Yes         ITT          4               0.49
  Holman, 2007 ([@B29])         474    12     Biphasic          P Aspart30 (×2)               61.7         64.1                                        8.6%                                                     0.53
                                              Prandial          Aspart (×3)                   61.7         64.1       Met + Su      ≤          Yes     8.6%            Yes         ITT          4               0.61
  Holman, 2007 ([@B29])         472    12     Prandial          P Aspart (×3)                 61.7         64.1                                        8.6%                                                     0.61
                                              Basal             Detemir                       61.7         64.1       Met + Su      ≤          Yes     8.4%            Yes         ITT          4               0.49
  Robbins, 2007 ([@B30])        315    6      Biphasic          P Lispro50 (×3)               57.7         49.8                                        7.8%                                                     0.7
                                              Basal             Glargine                      57.7         49.8       Met           ≤          No      7.8%            Yes         ITT          4               0.6
  Bretzel, 2008 ([@B31])        418    10.5   Prandial          P Lispro (×3)                 59.7         59                                          8.7%                                                     0.53
                                              Basal             Glargine                      60           52         Met, Su       ≤          Yes     8.7%            Yes         ITT          4               0.50
  Hirao, 2008 ([@B32])          117    6      Biphasic          P Aspart30 (×2)               58.5         58.7                                        10.6%                                                    ---
                                              Prandial          Lispro (×3)                   57.9         61.2       No            \<         Yes     10.6%           No          No ITT       2               ---
  Rosenstock, 2008 ([@B33])     374    6      Biphasic          P Lispro50 (×3)               55.4         53                                          8.8%                                                     1.2
                                              Basal-bolus       Lispro (×3) + Glargine        54           52         No Su         \<         No      8.9%            Yes         Complete     3               1.4
  Liebl, 2009 ([@B34])          715    4      Biphasic          P Aspart30 (×2)               61.7         63                                          8.4%                                                     0.62
                                              Basal-bolus       Aspart (×3) + Detemir         60.3         63         No            ≤          No      8.5%            Yes         ITT          2               0.88
  Buse, 2009 ([@B35])           2091   6      Biphasic          P Lispro25 (×2)               57           52.8                                        9.1%                                                     0.47
                                              Basal             Glargine                      57           52.8       Met/Su/Tzd    ≤          Yes     9.0%            Yes         ITT          4               0.4
  Raz, 2009 ([@B36])            1115   31     Basal             P Glargine                    60           63.3                                        8.3%                                                     0.52
                                              Prandial          Lispro (×3)                   60           63.3       No            \<         No      8.4%            Yes         ITT          4               0.60
  Strojek, 2009 ([@B37])        480    6      Basal             P Glargine                    56.1         41.2       Met +                            8.5%                                                     0.29
                                              Biphasic          Aspart30 (×1)                 55.9         46.8       Glimep        \<         Yes     8.5%            Yes         ITT          2               0.32
  Holman, 2009 ([@B38])         698    36     Biphasic          P Aspart30 (×2) + Aspart      61.7         64.1                                        8.6%                                                     0.78
                                              Basal-bolus       Aspart (×3) + Detemir         61.7         64.1       No            ≤          No      8.6%            Yes         ITT          4               0.97

CO, crossover group; P, parallel group; OHAs, oral hypoglycemic agents; Met, metformin; Su, sulfonylurea; Tzd, thiazolidinedione; ITT, intention to treat.

Nine trials enrolled insulin-naïve patients ([@B23],[@B25],[@B27]--[@B29],[@B31],[@B32],[@B35],[@B37]), six enrolled insulin-treated patients ([@B24],[@B30],[@B33],[@B34],[@B36],[@B38]), and one enrolled mixed patients ([@B26]). The median score of methodologic quality was 2.5 (interquartile range 2--4). Ten trials ([@B25],[@B29]--[@B31],[@B33]--[@B38]) used a predefined titration step of insulin doses. Eleven trials had a clear intention-to-treat analysis ([@B24]--[@B26],[@B28]--[@B31],[@B34]--[@B38]). Eleven trials ([@B23]--[@B27],[@B29]--[@B31],[@B33],[@B35],[@B37]) adopted combined treatment regimens of oral drugs plus insulin (whichever regimen); the most-represented oral drugs were metformin, a sulfonylurea, or a glitazone.

Biphasic versus basal {#s12}
---------------------

Ten trials ([@B23]--[@B30],[@B35],[@B37]) were eligible. Most included insulin-naïve patients ([@B23],[@B25],[@B27]--[@B30],[@B35],[@B37]) and adopted combined treatment regimens of oral drugs plus insulin ([@B23]--[@B27],[@B29],[@B30],[@B35],[@B37]). Compared with basal insulin, patients treated with biphasic insulin had a greater chance to reach the HbA~1c~ goal of \<7% (OR 1.88 \[95% CI 1.38--2.55\]; [Fig. 1*A*](#F1){ref-type="fig"}). There was no evidence of publication bias (*P* = 0.15). Heterogeneity was high (*I*^2^ = 68%) but diffuse. Compared with basal insulin, biphasic insulin was associated with a significant increase in hypoglycemic events (0.34 mean events/patient/30 days), but significant heterogeneity was observed (*I*^2^ = 64.9%). Exclusion of one trial ([@B27]) with the highest hypoglycemic rate completely eliminated heterogeneity (*I*^2^ = 0%; [Fig. 1*B*](#F1){ref-type="fig"}). Biphasic insulin was also associated with greater weight gain (mean difference, 1 kg \[95% CI 0.28--1.73\]) with high heterogeneity (*I*^2^ = 85.2%; [Fig. 1*C*](#F1){ref-type="fig"}). Final median (interquartile range) insulin dose was 0.5 units/kg (0.39--0.62) for biphasic and 0.41 units/kg (0.29--0.55) for basal insulin (*P* = 0.16).

###### 

Biphasic versus basal: *A*: Outcome, proportion (%) of patients with HbA~1c~ \<7%. *B*: Change in incidence of hypoglycemia. *C*: Change in weight. *N* = number of patients in each arm. \*Mixed-effects model: estimates adjusted for the correlation within studies and heterogeneity between studies; \^sensitivity analysis.
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Biphasic versus prandial {#s13}
------------------------

Three trials ([@B28],[@B29],[@B32]) were eligible. All trials included insulin-naïve patients. No difference between treatments was shown for achievement of HbA~1c~ goal (OR 1.04 \[95% CI 0.37--2.92\]; [Supplementary Fig. 2](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-1710/-/DC1)). There was no evidence of publication bias (*P* = 0.39). There was no mean (95% CI) difference in the incidence of hypoglycemia events/patient/30 days (−0.15 \[−0.57 to 0.27\]) or weight gain (0.1 kg \[−0.71 to 1.9\]) between the two regimens. One trial did not report insulin dose ([@B32]). For the remaining two trials, no difference in daily insulin dose was observed between the two regimens.

Prandial versus basal {#s14}
---------------------

Four studies ([@B28],[@B29],[@B31],[@B36]) were eligible. Compared with basal insulin, prandial insulin was associated with a nonsignificant chance of achievement the HbA~1c~ goal (OR 1.58 \[95% CI 0.77--3.23\]; [Supplementary Fig. 3](http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-1710/-/DC1)). An evidence of publication was detected (*P* = 0.07). A sensitivity analysis excluding one trial ([@B36]) gave significant results (OR 2.07 \[95% CI 1.16--3.69\]) with no evidence of heterogeneity (*I*^2^ = 0%) or publication bias (*P* = 0.37). Compared with basal insulin, prandial insulin was associated with a nonsignificant increase in the incidence of hypoglycemia, with high heterogeneity (*I*^2^ = 99.7%), which persisted elevated (*I*^2^ = 97.7%) after exclusion of one trial. Prandial insulin was also associated with a greater weight increase of borderline significance. Final median (interquartile range) insulin dose was 0.56 units/kg (0.51--0.60) for prandial and 0.49 units/kg (0.46--0.51) for basal insulin (*P* = 0.06).

Biphasic versus basal-bolus {#s15}
---------------------------

Three studies ([@B33],[@B34],[@B38]) were eligible. All trials included patients who were not insulin-naïve. The inclusion of the 3-year extension of the Treating to Target in Type 2 Diabetes (4-T) trial ([@B38]) in the present comparison was justified by the switching of 73.7% of the former original prandial and 81.5% of the basal regimen to a basal-bolus regimen. Compared with biphasic insulin, patients treated with a basal-bolus regimen had a higher chance to reach the HbA~1c~ goal (OR, 1.75 \[95% CI 1.11--2.77\]), with no evidence of heterogeneity (*I*^2^ = 0%; [Fig. 2](#F2){ref-type="fig"}). There was no evidence of publication bias (*P* = 0.78). There was no difference in incidence of hypoglycemia and weight gain between the two regimens. Final median (interquartile range) insulin dose was 0.78 units/kg (0.66--1.09) for biphasic insulin and 0.97 units/kg (0.90--1.29) for the basal-bolus regimen (*P* = 0.40).

![Biphasic versus basal-bolus. *A*: Outcome, proportion (%) of patients with HbA~1c~ \<7%. *B*: Change in incidence of hypoglycemia. *C*: Change in weight. *N* = number of patients in each arm. \*Mixed-effects model: estimates adjusted for the correlation within studies and heterogeneity between studies.](510fig2){#F2}

CONCLUSIONS {#s16}
===========

The ultimate goal of treatment of diabetes is improvement in microvascular and macrovascular complications, and death. Most trials included in this analysis were not specifically designed to evaluate these clinical outcomes. Although not ideal, HbA~1c~ is the most-used intermediate outcome to optimize glycemic control in a clinical setting. The ADA position statement on standards of medical care in diabetes ([@B4]) insists on the optimal HbA~1c~ target of \<7% for most nonpregnant adults, stressing the evidence that microvascular complications are better mitigated with this goal with respect to macrovascular complications (level of evidence A vs. B, respectively).

We found that biphasic and prandial insulin were both associated with a greater proportion of type 2 diabetic patients achieving the HbA~1c~ goal of \<7% compared with basal insulin. This effect was consistent across pooled trials. The basal-bolus regimen was better than biphasic, and in absolute terms, was the best regimen for the attainment of the HbA~1c~ goal. Ultimately, the proportion of patients with a HbA~1c~ goal of \<7% using the basal-bolus regimen was 63.5%. The effect of the different insulin regimens on hypoglycemia was quite similar across different comparisons, with the exception of a greater event rate with the biphasic compared with basal insulin. Biphasic and prandial insulin were both associated with greater weight gain compared with basal insulin, and this effect was also consistent across pooled trials.

Biphasic insulin is less effective than basal insulin in decreasing fasting glucose levels but is more effective in decreasing postprandial glucose levels ([@B10],[@B11]). Our analyses showed biphasic insulin was associated with more hypoglycemia than basal insulin (∼0.34 mean events/patient/30 days). These data are consistent with previous analyses ([@B9],[@B10]) showing that biphasic insulin is more likely to cause hypoglycemia than basal insulin, although in one study ([@B10]) the effect of the different insulin regimens could not be pooled in a meta-analysis. The incidence of hypoglycemia was similar between the other comparisons. The overall median incidence of hypoglycemia across all the comparisons was generally low, at 0.4 events/patient/30 days (range, 0--4.71 \[interquartile range 0.3--1.0\]). Biphasic and prandial insulin both caused more weight gain than basal insulin; however, weight gain was limited, at 1 and 1.94 kg, respectively. No difference in weight gain was found between biphasic versus prandial insulin or biphasic insulin versus the basal-bolus regimen.

The reduced frequency of insulin injections and glucose monitoring, associated with its inherent simplicity, has led to the basal insulin regimen becoming the first option in initiating insulin therapy in recent guidelines ([@B5]). Although successful for many patients, at least 60% of patients taking basil insulin were not able to reach the HbA~1c~ target. When the HbA~1c~ goal is not attained despite successful basal insulin dose titration, or when titration is limited by hypoglycemia, treatment is generally intensified by addition of prandial or biphasic insulin. According to our analysis, this escalation in insulin regimens from the simple basal to the complex basal-bolus may result in a further gain in the proportion of type 2 diabetic patients attaining the HbA~1c~ goal (63.5% with the basal-bolus regimen), which still leaves ∼33% of patients not at the target goal.

This study has limitations. The degree of heterogeneity was high for some comparisons, although results in most cases were qualitatively similar across studies in directions of the results. Moreover, sensitivity analysis eliminated heterogeneity in most cases. In addition, there was no evidence of publications bias.

Most studies had a short follow-up, and firm conclusions cannot be draw about the long-term comparative effectiveness of the various regimens. Any improvements seen in HbA~1c~ in these short-term trials may not be sustained over a longer period, although studies with longer follow-up gave similar results. Only one long-term study (mean patient participation after randomization was 963 days) was specifically designed for assessing cardiovascular outcomes in survivors to a first myocardial infarction comparing basal with biphasic insulin, but the study was stopped for lack of efficacy ([@B36]). Other long-term trials reported clinical outcomes as adverse events.

In conclusion, our analysis of 7,759 type 2 diabetic patients using insulin analogs indicates that the HbA~1c~ target \<7% can be achieved in 35 to 63.5%, depending on the particular insulin regimen. Basal insulin is associated with a lower proportion of diabetic patients at target compared with prandial or biphasic insulin, but with less hypoglycemia and weight gain compared with biphasic insulin. The best achievement rate is obtained with a basal-bolus regimen compared with biphasic insulin, without further risk of hypoglycemia or weight gain. More studies are needed to understand better the effect of insulin analogs on long-term diabetes complications.

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc10-1710/-/DC1>.
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